Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552730 · ClinicalTrials.gov registry record
Nerve Growth Factor for the Treatment of Cornea Disease
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 5
- Enrollment target
NCT04552730: Completed study, sponsored by Stanford University.
NCT04552730 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552730 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
Interventions
- DRUG Cenegermin-Bkbj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2021-05-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04552730
The ClinicalTrials.gov registry entry for NCT04552730 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cenegermin-Bkbj is the first listed.
NCT04552730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04552730 about?
NCT04552730 is a clinical study titled "Nerve Growth Factor for the Treatment of Cornea Disease". To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
What is the current status of trial NCT04552730?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2020-10-14. Estimated completion is 2021-05-04.
What interventions are being tested in trial NCT04552730?
The interventions under investigation include: Cenegermin-Bkbj (DRUG).
Who is sponsoring clinical trial NCT04552730?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.